Drug intelligence / Profile preview

cyclophosphamide + fludarabine + anti thymocyte globulin

Development stage
Unknown
Lead developer
Takeda
Modality
Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

This is a combination conditioning regimen used primarily in allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially for severe aplastic anemia. It consists of three agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA and suppresses the immune system. - Fludarabine, a purine analog that inhibits DNA synthesis and has immunosuppressive properties. - Anti-thymocyte globulin (ATG), a polyclonal antibody preparation targeting human T lymphocytes to induce profound immunosuppression by depleting T cells. The combination is designed to provide effective immunosuppression to prevent graft rejection and facilitate engraftment while reducing the risk of graft-versus-host disease (GVHD). This regimen is often used as an alternative to total body irradiation-based protocols. The main indications are conditioning prior to allogeneic stem cell transplantation for severe aplastic anemia and other hematologic disorders[1][2][3][4].

Brand names
CytoxanFludaraThymoglobulin
Other names
FCAFluCyATGFCA regimen
02

Targets

RNR (Ribonucleotide reductase)POLA2 (DNA polymerase alpha subunit B)MR1 (Thioesterase PNKD)CD3 (T-cell surface glycoprotein CD3)DNA

Beyond the preview

Go deeper on cyclophosphamide + fludarabine + anti thymocyte globulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + fludarabine + anti thymocyte globulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call